Discontinuation of imatinib therapy after achieving a molecular response
Top Cited Papers
- 1 October 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 104 (7), 2204-2205
- https://doi.org/10.1182/blood-2004-04-1335
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remissionLeukemia Research, 2004
- High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemiaBlood, 2004
- Molecular response to imatinib in late chronic-phase chronic myeloid leukemiaBlood, 2004
- Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003